Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

l minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. A replay of the webcast will be archived on the Sunesis website for two weeks until March 25, 2008.

About Sunesis' Oncology Programs

Sunesis has built a portfolio of product candidates in oncology focused on inhibition of the cell-cycle and survival signaling. Our lead product candidate, SNS-595, is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. SNS-595 is a specific DNA intercalator and topoisomerase II poison, causing replication-dependent site-selective double-strand DNA damage, irreversible G2 arrest and rapid apoptosis. A Phase 2 single agent clinical trial of SNS-595 in ovarian cancer and a Phase 1b clinical trial of SNS-595 combination with cytarabine in relapsed/refractory AML are both ongoing. SNS-032, a potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory CLL or multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other protein kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For further information o
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... USA (PRWEB) September 16, 2014 “Nature ... create the features that we desire in optical design,” ... at Montana State University. “As we explore surfaces and ... of those lessons were presented in San Diego in ... Light: Light in Nature ” chaired by Shaw and ...
(Date:9/16/2014)... --The emerging field of molecular electronics could take ... enabling the construction of tiny circuits from molecular ... would take on the roles currently played by ... of researchers from five Japanese and Taiwanese universities ... small-scale electronics: a molecule called picene. In a ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... 26, 2011 , Veeva Systems ... top 20 pharmaceutical companies, is replacing its legacy,on-premise ... the UK. Daiichi Sankyo will deploy Veeva CRM ... including integrated healthcare,specialty care, medical liaison scientists, and ...
... At an event at the University City Science ... U.S. Representatives Chaka Fattah (D-PA), Allyson Schwartz (D-PA) and ... that provides tax incentives for small and mid-sized businesses ... a targeted basis. The Life Sciences Jobs and ...
... Robert Ettinger, the founder of the cryonics movement and ... home in Clinton Township, Michigan, and has been frozen at ... temperatures after death in the hope that future technology will ... Mr. Ettinger wrote The Prospect of Immortality ...
Cached Biology Technology:Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 3Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 2Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 3Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 5Founder of Cryonics Movement Dies, is Frozen at Cryonics Institute 2
(Date:9/16/2014)... Health at the Mailman School of Public Health are ... and prenatal exposure to two phthalates used in a ... the journal Environmental Health Perspectives . , ... levels of the chemicals, butylbenzyl phthalate (BBzP) and di-n-butyl ... increase in risk of developing asthma between age 5 ...
(Date:9/16/2014)... maternal morbidity amongst women in Australia is increased ... published today (17 September) in BJOG: An ... Australians generally enjoy high standards of living; however, ... in particular between indigenous and non indigenous Australians. ... independent impact of socioeconomic position on severe maternal ...
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3
... researchers are a key step closer to making renewable petroleum ... a $2.2 million United States Department of Energy grant. ... made the critical step by figuring out how to use ... into ketones, which can be cracked to make hydrocarbon fuels. ...
... been used to treat heroin addicts for nearly 50 ... harmful effects from prolonged use. New research from the ... the brain and impairs the attention of experimental animals. ... morphine are known to weaken intellectual functions such as ...
... are many different kinds of crustaceans, ranging from the ... August to tiny relatives found in their millions in ... Daphnia pulex , is the first crustacean to have ... Gothenburg has made a surprising discovery. The sequencing ...
Cached Biology News:U of M researchers close in on technology for making renewable petroleum 2Long-term methadone treatment can affect the brain 2Surprising results in the first genome sequencing of a crustacean 2
... Psychology, The University of New South Wales, Sydney, ... Perth, Australia This is the Fourth Edition of ... It is a large format version (330 ... compact 3rd edition. This product number includes ...
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
Carrier Serum...
Biology Products: